Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65130 | 1.00 | CHRM1 (0.49) | CHRM1KCNH2ALDH1A1POLBMAPT | |
| SCHEMBL3212150 | 1.00 | CHRM1 (0.49) | CHRM1KCNH2ALDH1A1POLBMAPT | |
| SCHEMBL3195372 | 0.85 | CHRM1 (0.49) | CHRM1KCNH2ALDH1A1MAPTRAB9A | |
| SCHEMBL12175735 | 0.85 | CHRM1 (0.49) | CHRM1KCNH2ALDH1A1MAPTRAB9A | |
| SCHEMBL1228827 | 0.83 | CHRM1 (0.50) | CHRM1KCNH2ALDH1A1POLB | |
| SCHEMBL13461150 | 0.82 | CHRM1 (0.49) | CHRM1KCNH2ALDH1A1POLBMAPT | |
| SCHEMBL63296 | 0.82 | CHRM1 (0.49) | CHRM1KCNH2ALDH1A1POLBMAPT | |
| SCHEMBL65059 | 0.82 | CHRM1 (0.49) | CHRM1KCNH2ALDH1A1POLBMAPT | |
| SCHEMBL13433888 | 0.79 | CHRM1 (0.47) | CHRM1KCNH2ALDH1A1POLBMAPT | |
| SCHEMBL16556791 | 0.79 | CHRM1 (0.52) | CHRM1KCNH2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385930-B | Preparation method of primani | 药璞(上海)医药科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-115385930-A | Preparation method of Primanib | 药璞(上海)医药科技有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115385930-B | Preparation method of primani | 药璞(上海)医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115385930-B | Preparation method of primani | 药璞(上海)医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115385930-A | Preparation method of Primanib | 药璞(上海)医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115385930-A | Preparation method of Primanib | 药璞(上海)医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2254892-B1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-05-24 | — | — | US | disclosed |
| EP-1984369-A2 | NITROIMIDAZOLE COMPOUNDS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-08-21 | — | — | US | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7368579-B2 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-7368579-B2 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| WO-2007075872-A2 | NITROIMIDAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075872-A2 | NITROIMIDAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | CBR1, CBR3, DCXR | CHRM1 286/4885KCNH2 1417/4885ALDH1A1 836/4885 |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | CHRM1 286/4885KCNH2 1417/4885ALDH1A1 836/4885 |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | CHRM1 4498/4885KCNH2 3167/4885ALDH1A1 1997/4885 |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | CHRM1 286/4885KCNH2 1417/4885ALDH1A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.